Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Gedeon Richter
Deal Size : $19.5 million
Deal Type : Agreement
Richter and Mycenax Entered into an Asset Purchase Agreement of Biosimilar Tocilizumab
Details : Richter receives worldwide rights to develop, manufacture and commercialise the biosimilar tocilizumab for the treatment of rheumatoid arthritis.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : $3.0 million
April 29, 2020
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Gedeon Richter
Deal Size : $19.5 million
Deal Type : Agreement
Lead Product(s) : HMBD-002
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Hummingbird Bioscience
Deal Size : Undisclosed
Deal Type : Agreement
Details : Pre-clinical studies have shown that HMBD-002 can strongly inhibit tumor growth, both as a monotherapy and even more potently when combined with anti-PD(L)1 treatment.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
February 20, 2020
Lead Product(s) : HMBD-002
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Hummingbird Bioscience
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Tocilizumab
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 11, 2018
Lead Product(s) : Tocilizumab
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ENIA11
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : TSH Biopharm Corporation Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 19, 2016
Lead Product(s) : ENIA11
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : TSH Biopharm Corporation Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 08, 2013
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2012
Lead Product(s) : Methotrexate
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
